Decreased ATP levels in response to CADD522 were observed when cells were treated with CADD522 for a relatively long period of time (24~48 hr) (Supplementary Figure 4C), and also were generally observed in BC cells regardless of their RUNX2 status. Here, RUNX2 is linked to breast cancer.